Initially deployed against CD19-positive blood malignancies like lymphoma and acute lymphoblastic leukemia (ALL), CAR T-cell therapies targeting CD19 have gained clinical approval from the U.S. Food and Drug Administration [7]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.